NCT03159676 is a clinical trial of Proton beam in Prostate Cancer, sponsored by Mayo Clinic.

Who is sponsoring NCT03159676?

NCT03159676 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03159676?

Interventions in NCT03159676: Proton beam.

What condition does NCT03159676 study?

NCT03159676 studies Prostate Cancer.

Is NCT03159676 still recruiting?

NCT03159676 is currently completed. Last updated 25 February 2026.

Last reviewed 2026-02-25 · How we verify

NCT03159676

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

Completed Last updated 25 February 2026

What this trial tests

trial testing Proton beam in Prostate Cancer in 150 participants. Completed in 31 December 2024.

Timeline

12 May 2017

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Mayo Clinic
Status	Completed
Study type	OBSERVATIONAL
Enrollment	150
Start date	12 May 2017
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across United States

Drugs / interventions tested

Proton beam

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Mayo Clinic

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stereotactic ablative body radiotherapy (SABR), or stereotactic body radiotherapy (SBRT), is a specialized form of radiotherapy used to treat prostate cancer with five treatments over two weeks, compared with a conventional eight-week or longer treatment course. The purpose of this trial is to investigate the effect that proton-based SABR has on quality-of-life in patients with localized prostate cancer. The evaluation and treatment will otherwise follow standard of care, and is not considered investigational.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Consensus Statement on Proton Therapy for Prostate Cancer.
Bryant CM, Henderson RH, Nichols RC, Mendenhall WM, et al · · 2021 · cited 23× · PMID 34722807 · DOI 10.14338/ijpt-20-00031.1
Stereotactic body proton therapy for liver tumors: Dosimetric advantages and their radiobiological and clinical implications.
Arscott WT, Thompson RF, Yin L, Burgdorf B, et al · · 2018 · cited 17× · PMID 33458411 · DOI 10.1016/j.phro.2018.11.004
Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer.
Gao RW, Ma J, Pisansky TM, Kruse JJ, et al · · 2024 · PMID 38827121 · DOI 10.1016/j.ijpt.2024.100015

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03159676 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 25 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03159676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing